• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by SCYNEXIS Inc.

    3/28/24 4:30:21 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SCYX alert in real time by email
    S-8 1 form_s-8_-_march_28_2024.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 28, 2024

    Registration No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    SCYNEXIS, Inc.

    (Exact name of Registrant as specified in its charter)

     

     

     

     

     

     

    Delaware

    56-2181648

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

    1 Evertrust Plaza, 13th Floor

    Jersey City, New Jersey 07302-6548

    (201) 884-5485

    (Address of principal executive offices) (Zip code)

     

     

    SCYNEXIS, Inc. 2014 Equity Incentive Plan

    SCYNEXIS, Inc. 2014 Employee Stock Purchase Plan

    (Full title of the plan)

     

     

    David Angulo, M.D.

    Chief Executive Officer

    SCYNEXIS, Inc.

    1 Evetrust Plaza, 13th Floor

    Jersey City, NJ 07302-6548

    (201) 884-5485

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Copies to:

    Matthew B. Hemington

    Cooley LLP

    3175 Hanover Street

    Palo Alto, California 94304

    (650) 843-5000


    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

     

    

     

    Accelerated filer

     

    

    Non-accelerated filer

     

    ☒

     

    Smaller reporting company

     

    ☒

    Emerging growth company

     

    

     

     

     

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

     


    EXPLANATORY NOTE

     

    SCYNEXIS, Inc. (the “Registrant ”) is filing this Registration Statement on Form S-8 for the purpose of registering an aggregate of 1,919,903 additional shares of its Common Stock, issuable to eligible persons under the SCYNEXIS, Inc. 2014 Equity Incentive Plan and the SCYNEXIS, Inc. 2014 Employee Stock Purchase Plan (collectively, the “Plans” ), which Common Stock is in addition to the shares of Common Stock previously registered on the following Form S-8s (collectively, the “Prior Form S-8s” ) pursuant to the Plans:

    •
    the Registrant’s Form S-8 filed on May 16, 2014 (File No. 333-196007);
    •
    the Registrant’s Form S-8 filed on December 18, 2014 (File No. 333-201048);
    •
    the Registrant’s Form S-8 filed on March 17, 2015 (File No. 333-202830);
    •
    the Registrant’s Form S-8 filed on June 6, 2015 (File No. 333-204771);
    •
    the Registrant's Form S-8 filed on March 7, 2016 (File No. 333-209997);
    •
    the Registrant's Form S-8 filed on March 13, 2017 (File No. 333-216652);
    •
    the Registrant's Form S-8 filed on March 13, 2018 (File No. 333-223624);
    •
    the Registrant's Form S-8 filed on March 14, 2019 (File No. 333-230278);
    •
    the Registrant's Form S-8 filed on March 11, 2020 (File No. 333-237077);
    •
    the Registrant’s Form S-8 filed on March 29, 2021 (File No. 333-254831);
    •
    the Registrant’s Form S-8 filed on March 30, 2022 (File No. 333-263962);
    •
    the Registrant's Form S-8 filed on March 31, 2023 (File No. 333-271018); and
    •
    the Registrant's Form S-8 filed on July 18, 2023 (File No. 333-273305).

    Pursuant to General Instruction E to Form S-8, the contents of the Prior Form S-8s are incorporated herein by reference and made a part hereof.

     

    PART II

     

    Item 3. Incorporation of Documents by Reference.

    The following documents filed by SCYNEXIS, Inc. (the “Registrant”) with the Securities and Exchange Commission are incorporated by reference into this Registration Statement:

    (a) The Registrant’s Annual Report on Form 10-K filed on March 28, 2024.

    (b) The Registrant’s Current Report on Form 8-K filed on January 2, 2024.

    (c) The description of the Registrant’s common stock which is contained in the registration statement on Form 8-A filed on March 19, 2014, (File No. 001-36365) under the Exchange Act of 1934, as amended (the “Exchange Act”), including any amendments or reports filed for the purpose of updating such description, including Exhibit 4.2 to the Registrant’s Annual Report on Form 10-K filed on March 31, 2023.

    (d) The other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Item 8. Exhibits

    Exhibit

    Number

    Description

    4.1

    Amended and Restated Certificate of Incorporation of SCYNEXIS, Inc., as currently in effect (Filed as Exhibit 3.1 to our Current Report on Form 8-K (File No. 001-36365), filed with the Securities and Exchange Commission on May 12, 2014, and incorporated herein by reference).

     

     

     

    4.2

     

    Certificate of Amendment of Amended and Restated Certificate of Incorporation of SCYNEXIS, In. (Filed as Exhibit 3.2 to our Form 10-Q, filed with the Securities and Exchange Commission on August 7, 2019, SEC File No. 001-36365, and incorporated by reference here).

     

     

    4.3

     

    Certificate of Amendment of Amended and Restated Certificate of Incorporation of SCYNEXIS, Inc. (Filed as Exhibit 3.1 to our Form 8-K, filed with the Securities and Exchange Commission on July 16, 2020, SEC File No. 001-36365, and incorporated by reference here).


     

     

     

    4.4

     

    Certificate of Amendment of Amended and Restated Certificate of Incorporation of SCYNEXIS, Inc. (Filed as Exhibit 3.4 to our Form 10-Q, filed with the Securities and Exchange Commission on November 9, 2022, SEC File No. 001-36365, and incorporated by reference here).

     

     

     

    4.5

    Amended and Restated Bylaws of SCYNEXIS, Inc., as currently in effect (Filed as Exhibit 3.4 to our Registration Statement on Form S-1 (File No. 333-194192), filed with the Securities and Exchange Commission on February 27, 2014, and incorporated herein by reference).

    5.1

    Opinion of Cooley LLP.

    23.1

    Consent of Cooley LLP (included in Exhibit 5.1).

    23.2

    Consent of Independent Registered Public Accounting Firm.

    24.1

    Power of Attorney (included on the signature page of this Form S-8).

    99.3

    SCYNEXIS, Inc. 2014 Equity Incentive Plan (Filed as Exhibit 10.3 to our Form 10-Q (File No. 001-36365), filed with the Securities and Exchange Commission on August 10, 2020, and incorporated herein by reference).

    99.4

     

     

    SCYNEXIS, Inc. 2014 Employee Stock Purchase Plan (Filed as Exhibit 99.1 to our Form S-8 (SEC File No. 333-273305), filed with the Securities and Exchange Commission on July 18, 2023, and incorporated herein by reference).

     

     

     

    107

     

    Filing Fee Table


     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Jersey City, State of New Jersey, on this 26th day of March, 2024.

    SCYNEXIS, INC.

    By:

    /s/ David Angulo

    David Angulo, M.D.

    Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoint David Angulo, M.D. and Scott Sukenick, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signatures

    Title

    Date

    /s/ David Angulo, M.D.

    Director, Chief Executive Officer and President

    (Principal Executive Officer)

    March 26, 2024

    David Angulo, M.D.

     

     

     

    /s/ Ivor Macleod

    Chief Financial Officer

    (Principal Financial and Accounting Officer )

    March 26, 2024

    Ivor Macleod

     

     

     

    /s/ Guy Macdonald

    Chairman of the Board of Directors

    March 26, 2024

    Guy Macdonald

     

     

     

    /s/ Armando Anido

    Director

    March 26, 2024

    Armando Anido

     

     

     

    /s/ Steven C. Gilman

    Director

    March 26, 2024

    Steven C. Gilman, Ph.D.

     

     

     

    /s/ Ann F. Hanham

    Director

    March 26, 2024

    Ann F. Hanham, Ph.D.

     

     

    /s/ David Hastings

    Director

    March 26, 2024

    David Hastings

     

     

     

    /s/ Brian Philippe Tinmouth

    Director

    March 26, 2024

    Brian Philippe Tinmouth

     

     

     

     


    Get the next $SCYX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SCYX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SCYX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)

    JERSEY CITY, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced upcoming presentations highlighting data on the Company's second-generation fungerp drug candidate, SCY-247, at the inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI), which is taking place from January 28 to 30, 2026, in Las Vegas, Nevada. "We are pleased to participate in this important inaugural multidisciplinary meeting focused on addressing the significant threat of antimicrobial resistance," said David Angulo, M.D., Presi

    1/28/26 8:00:00 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247

    The QIDP designation will ensure at least 10 years of market exclusivity for SCY-247 following approval Recent articles highlight the growing threat from a rapidly spreading, multi-drug resistant, Candida auris fungal infection JERSEY CITY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the U.S. Food and Drug Administration ("FDA") has granted the Company Qualified Infectious Disease Product (QIDP) and Fast Track Designations for its second-generation triterpenoid antifungal therapy, SCY-247. "Receiving FDA's QIDP

    1/21/26 8:00:00 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

    JERSEY CITY, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has received an additional 180-calendar-day extension from the Nasdaq Stock Market ("Nasdaq") to regain compliance with the minimum bid price requirement, as outlined in Nasdaq Listing Rule 5550(a)(2). The Company now has until June 15, 2026, to meet the requirement for its shares of common stock to maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days. Nasdaq granted the extension after determining that SC

    12/22/25 8:00:00 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCYX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Angulo Gonzalez David bought $27,400 worth of shares (20,000 units at $1.37), increasing direct ownership by 4% to 507,871 units (SEC Form 4)

    4 - SCYNEXIS INC (0001178253) (Issuer)

    9/16/24 8:00:27 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCYX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Macleod Ivor was granted 129,833 shares, increasing direct ownership by 48% to 398,529 units (SEC Form 4)

    4 - SCYNEXIS INC (0001178253) (Issuer)

    2/2/26 4:03:14 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer Sukenick Scott was granted 129,833 shares, increasing direct ownership by 29% to 574,539 units (SEC Form 4)

    4 - SCYNEXIS INC (0001178253) (Issuer)

    2/2/26 4:02:11 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Angulo Gonzalez David was granted 391,333 shares, increasing direct ownership by 46% to 1,244,431 units (SEC Form 4)

    4 - SCYNEXIS INC (0001178253) (Issuer)

    2/2/26 4:01:08 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCYX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by SCYNEXIS Inc.

    SCHEDULE 13G/A - SCYNEXIS INC (0001178253) (Subject)

    1/8/26 8:19:28 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by SCYNEXIS Inc.

    SCHEDULE 13G/A - SCYNEXIS INC (0001178253) (Subject)

    11/14/25 2:27:47 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by SCYNEXIS Inc.

    SCHEDULE 13G/A - SCYNEXIS INC (0001178253) (Subject)

    11/12/25 1:09:48 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCYX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Aegis Capital reiterated coverage on SCYNEXIS with a new price target

    Aegis Capital reiterated coverage of SCYNEXIS with a rating of Buy and set a new price target of $35.00 from $40.00 previously

    6/7/21 9:58:05 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aegis Capital reiterated coverage on SCYNEXIS with a new price target

    Aegis Capital reiterated coverage of SCYNEXIS with a rating of Buy and set a new price target of $40.00 from $45.00 previously

    4/12/21 12:54:40 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group reiterated coverage on SCYNEXIS with a new price target

    Maxim Group reiterated coverage of SCYNEXIS with a rating of Buy and set a new price target of $22.00 from $17.00 previously

    2/17/21 2:23:39 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCYX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for BREXAFEMME issued to SCYNEXIS, INC

    Submission status for SCYNEXIS, INC's drug BREXAFEMME (ORIG-1) with active ingredient IBREXAFUNGERP has changed to 'Approval' on 06/01/2021. Application Category: NDA, Application Number: 214900, Application Classification: Type 1 - New Molecular Entity

    6/2/21 11:20:46 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for BREXAFEMME issued to SCYNEXIS, INC

    Submission status for SCYNEXIS, INC's drug BREXAFEMME (SUPPL-1) with active ingredient IBREXAFUNGERP has changed to 'Approval' on 06/01/2021. Application Category: NDA, Application Number: 214900, Application Classification: Type 1 - New Molecular Entity

    6/2/21 9:57:42 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCYX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SCYNEXIS Inc.

    SC 13G/A - SCYNEXIS INC (0001178253) (Subject)

    11/14/24 7:07:26 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by SCYNEXIS Inc.

    SC 13G/A - SCYNEXIS INC (0001178253) (Subject)

    11/6/24 8:56:32 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by SCYNEXIS Inc.

    SC 13G/A - SCYNEXIS INC (0001178253) (Subject)

    10/7/24 1:38:20 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCYX
    Financials

    Live finance-specific insights

    View All

    GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection

    Brexafemme complements GSK's industry-leading infectious disease portfolio with an FDA approved treatment for vulvovaginal candidiasisSCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royaltiesSCYNEXIS retains rights to all other assets derived from enfumafungin, with GSK having a right of first negotiation to these pre-clinical and discovery stage assetsSCYNEXIS to host an investor call and webcast at 8:30 a.m. EDT today LONDON and JERSEY CITY, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- GSK plc (NYSE:GSK) and SCYNEXIS, Inc. (NASDAQ:SCYX), today announced they have entered into an exclusive licence agreement for Brexafemme (i

    3/30/23 7:05:00 AM ET
    $GSK
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SCYNEXIS Reports Third Quarter 2022 Financial Results and Provides Corporate Update

    SCYNEXIS recently announced new strategic direction to refocus its resources on the clinical development of ibrexafungerp for severe, hospital-based indications.Ivor Macleod, a 30-year biopharma veteran, joined SCYNEXIS as Chief Financial Officer.Marco Taglietti, M.D., to retire as President and Chief Executive Officer of SCYNEXIS and step down from the Board of Directors on December 31, 2022. David Angulo, M.D., Chief Medical Officer of SCYNEXIS will become President and Chief Executive Officer and join the Board effective January 1, 2023.BREXAFEMME® (ibrexafungerp tablets) prescriptions continued to grow in Q3 2022, increasing 13% over Q2 2022, generating net revenues of $1.6 million in Q3

    11/9/22 7:00:00 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SCYNEXIS to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 9

    JERSEY CITY, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at 8:30 a.m. EDT on Wednesday, November 9, 2022, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2022. Conference call and webcast details: Investors (domestic): (844) 826-3033Investors (international): (412) 317-5185Webcast:  LinkConference ID: 10172836 A live audio webcast can be accessed by visiting the Investor Relations section of the Company'

    11/1/22 8:30:00 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCYX
    Leadership Updates

    Live Leadership Updates

    View All

    AUROBAC THERAPEUTICS welcomes two new independent members to its Board: Manos Perros, as Chairman, and Marco Taglietti

    Lyon - France, July 24, 2023 (GLOBE NEWSWIRE) -- AUROBAC THERAPEUTICS WELCOMES TWO NEW INDEPENDENT MEMBERS TO ITS BOARD: MANOS PERROS, AS CHAIRMAN, AND MARCO TAGLIETTI Dr Manos Perros and Dr Marco Taglietti are appointed new Independent Members of the Board of AUROBAC THERAPEUTICSDr Perros becomes Chairman of the Board These new appointments bring extensive US and international experience in company leadership and development of anti-infectives from R&D to commercialization Lyon (France), Thursday July 24, 2023 AUROBAC THERAPEUTICS SAS, a biopharmaceutical company developing the next generation of products to fight antimicrobial resistance (AMR), is delighted to announce th

    7/24/23 8:00:00 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SCYNEXIS Reports First Quarter 2021 Financial Results and Provides Corporate Update

    Secured non-dilutive funding of approximately $35 million thus far in 2021, including licensing payments from Hansoh Pharma, the first tranche from a term loan agreement with Hercules and Silicon Valley Bank, and the monetization of the 2020 New Jersey NOLsAppointed Christine Coyne as Chief Commercial Officer to lead the launch of ibrexafungerp (Brexafemme®) for the treatment of vaginal yeast infections, following expected approval by June 1st Began dosing patients in a Phase 1 trial of the IV formulation of ibrexafungerpFurther strengthened balance sheet and projected cash runway into 2023 JERSEY CITY, N.J., May 17, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology c

    5/17/21 8:30:00 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SCYNEXIS Appoints Accomplished Commercial Executive Christine Coyne as Chief Commercial Officer to Lead the Brexafemme® Launch

    Strengthening the management team with deep anti-infective commercial expertise across hospital and community settings ahead of anticipated approval of Brexafemme (ibrexafungerp) in June 2021 and H2:2021 launch JERSEY CITY, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the appointment of Christine Coyne as Chief Commercial Officer, effective May 10, 2021. Ms. Coyne will play a significant role in the anticipated U.S. launch and commercialization of Brexafemme, the expected trade name for ibrexafungerp, an oral antifungal p

    5/11/21 8:30:00 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care